Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for You?
You have likely already done the research. You know GLP-1 medications work. Now you are comparing two options: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Both are once-weekly injectable medications supported by strong clinical trial data.
The comparison is not about which medication is “better” in general. It is about which option aligns with your goals, tolerance, and medical history. This guide breaks down what the data shows and what factors actually influence decision-making in clinical practice.
How GLP-1 Medications Work
GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone released by the gut after eating. They signal the brain to reduce hunger, slow gastric emptying so fullness lasts longer, and improve insulin response. The result is reduced caloric intake without relying solely on willpower.
Semaglutide activates GLP-1 receptors. Tirzepatide activates GLP-1 receptors along with a second pathway, GIP, which also plays a role in metabolic regulation. This mechanistic difference underlies the performance differences seen in clinical data.
Semaglutide: What It Is and How It Works
Semaglutide is a GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. It reduces hunger signaling, slows gastric emptying, and improves insulin sensitivity. Patients typically titrate from a 0.25 mg starting dose to a 2.4 mg maintenance dose over 8–12 weeks, thereby reducing GI side effects during the adjustment period.
The STEP 1 trial, a large randomized, placebo-controlled study evaluating semaglutide for chronic weight management, found that adults receiving 2.4 mg weekly lost an average of 15% of body weight over 68 weeks, compared with 2.4% in the placebo group. For a 200-pound patient, that equates to roughly 30 pounds.
In the United States, semaglutide is marketed under the brand names Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management at the 2.4 mg dose). The active ingredient is the same; the indication and dosing differ.
Tirzepatide: What It Is and How It Works
Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both hormone pathways simultaneously, producing an additive effect on appetite regulation and metabolic function. Like semaglutide, it is administered as a once-weekly injection and follows a gradual titration schedule, typically from 2.5 mg to a 15 mg maintenance dose over approximately 20 weeks.
The SURMOUNT-1 trial evaluated tirzepatide in adults with obesity or overweight plus at least one weight-related comorbidity. At the 15 mg dose, participants lost up to 22.5% of body weight over 72 weeks, representing one of the highest average weight loss outcomes reported in a phase 3 obesity medication trial at the time of publication. Lower doses (5 mg and 10 mg) produced 15–19.5% weight loss.
Tirzepatide is marketed under the brand names Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). As with semaglutide, the active ingredient remains the same across indications.
How They Compare
Mechanism
Semaglutide targets GLP-1 receptors only. Tirzepatide targets both GLP-1 and GIP receptors. This dual-pathway mechanism contributes to the greater average weight loss observed with tirzepatide.
Average weight loss in clinical trials
Semaglutide: approximately 15% body weight loss over 68 weeks (STEP 1)
Tirzepatide: up to 22.5% over 72 weeks (SURMOUNT-1)
A 2023 real-world observational study published in JAMA Internal Medicine found that patients on tirzepatide experienced greater weight loss than those on semaglutide over 12 months.
Side effects
Both medications share a similar gastrointestinal side effect profile, including nausea, vomiting, constipation, and diarrhea. These effects are most pronounced during dose titration.
Tirzepatide trial data have not shown a consistently higher burden of side effects despite its greater efficacy. Individual tolerance varies, and some patients may respond better to one medication than the other.
Dosing
Both medications are administered as once-weekly subcutaneous injections. Semaglutide typically reaches maintenance dosing over 8–12 weeks. Tirzepatide titration extends to approximately 20 weeks, allowing for a more gradual adjustment period.
Which One Is Right for You?
Clinical trial averages are a starting point, not a prescription. Several factors influence the decision in practice.
Prior GLP-1 experience
Patients who have used semaglutide with partial results may benefit from tirzepatide’s dual mechanism. For those new to GLP-1 therapy with moderate weight-loss goals, semaglutide offers a well-established safety profile and a shorter titration timeline.
GI tolerance
Individual response varies. Some patients tolerate tirzepatide better due to its slower titration schedule, while others find semaglutide easier to manage.
Cost and long-term access
Sustainability matters. A medication that produces stronger results in clinical trials may not be the better option if it cannot be maintained long-term due to cost or access limitations.
None of these factors replaces a clinical evaluation. Lab results, medical history, and current medications all influence the appropriate choice.
How Coastal Healthcare Prescribes GLP-1 Medications
Before prescribing GLP-1 therapy, Kirsten Lamb, NP, reviews a comprehensive lab panel, including metabolic markers, A1C, thyroid function, and lipids. These labs establish baseline health, identify contraindications, and help determine the most appropriate medication.
Ongoing management, including dose adjustments, lab review, and prescription renewal, is handled via telehealth for most patients after the initial evaluation.
Each patient at Coastal Healthcare is managed directly by Kirsten. There are no rotating providers or handoffs, which supports consistent decision-making and follow-up care over time. See the full medical weight-loss program for details on intake and the ongoing process.
Frequently Asked Questions
Is Ozempic the same as semaglutide?
Ozempic is a brand name for semaglutide approved for type 2 diabetes, typically at doses up to 2 mg weekly. Wegovy is the brand name approved for chronic weight management at a dose of 2.4 mg. The active ingredient is the same; the indication and dosing differ.
How does Mounjaro compare to Ozempic for weight loss?
Clinical trial data show tirzepatide (Mounjaro/Zepbound) producing greater average weight loss than semaglutide (Ozempic/Wegovy). SURMOUNT-1 reported up to 22.5% weight loss at the 15 mg tirzepatide dose, compared to approximately 15% for semaglutide in STEP 1. Real-world data has supported this difference.
Is tirzepatide safer than semaglutide?
Both medications carry the same class-level boxed warning related to thyroid C-cell tumors (based on rodent data) and share similar contraindications. Current data does not show a meaningful difference in safety profile between the two. Individual responses vary, and both require clinical evaluation prior to prescribing.
Does tirzepatide cause more side effects than semaglutide?
Both medications share similar GI side effects, including nausea, constipation, vomiting, and diarrhea. Tirzepatide has not demonstrated a consistently higher burden of side effects in clinical trials. Individual tolerance varies.
Which GLP-1 medication is covered by insurance?
Coverage varies by plan. Wegovy and Zepbound often require prior authorization or may be excluded. Ozempic and Mounjaro may have broader coverage when prescribed for diabetes, though variability remains. Coastal Healthcare operates as a cash-pay clinic, so insurance does not determine prescribing decisions.
Can I get semaglutide or tirzepatide via telehealth in Florida?
Yes. After initial evaluation and lab review, most follow-up care can be managed through telehealth. Coastal Healthcare provides GLP-1 management for patients across Florida. Initial labs may require an in-person draw depending on your situation. Schedule a virtual consultation to discuss eligibility and next steps.
Talk to Coastal Healthcare About GLP-1 Options
Both semaglutide and tirzepatide are effective medications. Choosing between them requires a clinical conversation, not just a comparison chart. Kirsten Lamb, NP, sees patients from our Sanibel Island clinic and via telehealth throughout Florida.
Schedule a virtual consultation or call (239) 428-0833
About the Author
Kirsten Lamb, NP, is a Board-Certified Family Nurse Practitioner with more than 10 years of advanced practice nursing experience. She holds prescriptive authority for GLP-1 medications in Florida and personally manages all patients at Coastal Healthcare. Learn more about Kirsten's approach.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results may vary. GLP-1 medications carry risks and contraindications that must be evaluated by a licensed healthcare provider.